FrancophonIA/ELRC3.0 huggingface dataset:
English: Because of the possibility of infertility as a consequence of Dacogen therapy, men should seek advice on conservation of sperm and female patients of childbearing potential should seek consultation regarding oocyte cryopreservation prior to initiation of treatment.
Slovenian: Zaradi možnosti, da bi zdravljenje z zdravilom Dacogen povzročilo neplodnost, naj se moški posvetujejo glede shranjevanja sperme, ženske v rodni dobi pa glede zamrzovanja jajčec še pred začetkom zdravljenja.
English: • Difficultly with moving, speaking or understanding or seeing; sudden severe headache, seizure, numbness or weakness in any part of the body.
Slovenian: • Težave pri gibanju, govorjenju ali razumevanju ali težave z vidom, nenaden hud glavobol, epileptičen napad, odrevenelost ali šibkost kateregakoli dela telesa.
English: Data from the literature also indicate that decitabine has adverse effects on all aspects of the reproductive cycle, including fertility, embryo-foetal development and post-natal development.
Slovenian: Po podatkih iz literature decitabin škodljivo deluje na vse faze reproduktivnega cikla, vključno s plodnostjo, z razvojem zarodka in plodu in s postnatalnim razvojem.
English: The use of Dacogen was studied in an open-label, randomised, multicentre Phase III study (DACO-016) in subjects with newly diagnosed de novo or secondary AML according to the WHO classification.
Slovenian: Uporabo zdravila Dacogen so proučevali v odprti, randomizirani, multicentrični študiji faze III (DACO-016) pri bolnikih z nedavno odkrito de novo ali sekundarno AML po klasifikaciji SZO.
English: In clinical studies, the majority of patients had baseline Grade 3/4 myelosuppression.
Slovenian: Pri večini bolnikov v kliničnih študijah je bila izhodiščna mielosupresija stopnje 3/4.
English: After preparing the medicine, it contains less than 1 mmol (39 mg) of potassium per dose, i.e. essentially ‘potassium- free'.
Slovenian: Po pripravi zdravilo vsebuje manj kot 1 mmol (39 mg) kalija na odmerek, kar v bistvu pomeni ‘brez kalija'.
English: Haematological adverse drug reactions should be managed by routine monitoring of complete blood counts and early administration of supportive treatments as required.
Slovenian: Hematološke neželene učinke je treba odkrivati z rutinskim določanjem celotne krvne slike, nato pa jih po potrebi zdraviti z uvedbo čimprejšnjega podpornega zdravljenja.
English: Dacogen is contraindicated during breast-feeding; therefore, if treatment with this medicine is required, breast-feeding must be discontinued (see section 4.3).
Slovenian: Uporaba zdravila Dacogen je v času dojenja kontraindicirana, zato mora bolnica prekiniti z dojenjem v primeru, da potrebuje zdravljenje s tem zdravilom (glejte poglavje 4.3).
English: In addition, in vitro data show that decitabine is a poor P-gp substrate.
Slovenian: Poleg tega in vitro podatki kažejo, da je decitabin le v manjši meri substrat P-glikoproteina.
English: Results from a human mass-balance study and in vitro experiments mentioned above indicated that the CYP enzymes are unlikely to be involved in the metabolism of decitabine.
Slovenian: Rezultati študije masnega ravnovesja pri ljudeh in zgoraj navedenih preizkusov in vitro kažejo, da encimski sistem CYP po vsej verjetnosti ni vpleten v presnovo decitabina.
English: Women of childbearing potential/Contraception in males and females Women of childbearing potential must use effective contraceptive measures and avoid becoming pregnant while being treated with Dacogen.
Slovenian: Ženske v rodni dobi/Kontracepcija pri moških in ženskah Ženske v rodni dobi morajo v času zdravljenja z zdravilom Dacogen uporabljati učinkovito kontracepcijo in paziti, da ne bi zanosile.
English: The effects of renal or hepatic impairment, gender, age or race on the pharmacokinetics of decitabine have not been formally studied.
Slovenian: Dodatne informacije pri posebnih skupinah bolnikov Vpliva okvare ledvic oziroma jeter, spola, starosti in rasne pripadnosti na farmakokinetiko decitabina niso formalno proučevali.
English: Caution should be exercised in the administration of Dacogen to patients with hepatic impairment and in patients who develop signs or symptoms of hepatic impairment.
Slovenian: Pri odmerjanju zdravila Dacogen bolnikom z okvaro jeter in bolnikom, pri katerih se pojavijo znaki ali simptomi okvare jeter, je potrebna previdnost.
English: Very common pneumonia* urinary tract infection* All other infections (viral, bacterial, fungal)*
Slovenian: Infekcijske in parazitske bolezni zelo pogosti pljučnica okužba sečil vse druge vrste okužb (virusne, bakterijske, glivične)*,
English: Outcomes
Slovenian: izidi
English: HR (95% CI): 0.85 (0.69, 1.04) Logrank p-value: 0.1079
Slovenian: razmerje tveganja 95% IZ: 0,85 (0,69, 1,04) vrednost p za logrank test: 0,1079
English: Impact of co-administered medicinal products on decitabine Cytochrome (CYP) 450-mediated metabolic interactions are not anticipated as decitabine metabolism is not mediated by this system but by oxidative deamination.
Slovenian: Metaboličnih interakcij zaradi presnove s citokromom (CYP) 450 ni pričakovati, saj se decitabin ne presnavlja s tem encimskim sistemom, ampak z oksidativno deaminacijo.
English: • mouth or tongue ulcers
Slovenian: • razjede v ustih ali na jeziku
English: See the package leaflet for further information.
Slovenian: Za podrobnejše podatke glejte navodilo za uporabo.
English: Complete blood and platelet counts should be performed regularly, as clinically indicated and prior to each treatment cycle.
Slovenian: Celotno krvno sliko in koncentracijo trombocitov je treba določati v rednih presledkih, poleg tega pa še vsakokrat, kadar je to klinično indicirano in pred vsakim krogom zdravljenja.
English: The population pharmacokinetic (PK) parameters of decitabine were pooled from 3 clinical studies in 45 patients with AML or myelodysplastic syndrome (MDS) utilizing the 5-Day regimen.
Slovenian: Za oceno parametrov populacijske farmakokinetike decitabina so združili podatke iz 3 kliničnih študij, v katere je bilo vključenih 45 bolnikov, ki so imeli AML ali mielodisplastični sindrom (MDS) in so jih zdravili po 5-dnevni shemi.
English: • Your doctor, nurse or pharmacist is responsible for storing Dacogen.
Slovenian: • Za shranjevanje zdravila Dacogen je odgovoren vaš zdravnik, farmacevt ali medicinska sestra.
English: Formal carcinogenicity studies have not been performed with decitabine.
Slovenian: Formalnih študij kancerogenosti z decitabinom niso opravili.
English: For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.
Slovenian: Za navodila za rekonstitucijo in razredčevanje zdravila pred apliciranjem glejte poglavje 6.6.
English: • an infection of the blood caused by bacteria - this may be a sign of a low level of white blood cells
Slovenian: • bakterijska okužba krvi - je lahko znak zmanjšanega števila belih krvnih celic
English: Table 1: Adverse drug reactions identified with Dacogen
Slovenian: Preglednica 1: Neželeni učinki pri uporabi zdravila Dacogen
English: Method of administration Dacogen is administered by intravenous infusion.
Slovenian: Zdravilo Dacogen je treba aplicirati z intravensko infuzijo.
English: This leaflet was last revised in MM/YYYY
Slovenian: Navodilo je bilo nazadnje revidirano dne {MM/LLLL}
English: Information on special populations was derived from pharmacokinetic data from the 3 studies noted above, and from one Phase I study in MDS subjects, (N = 14; 15 mg/m2 x 3-hours q8h x 3 days).
Slovenian: Podatki o posebnih skupinah bolnikov izhajajo iz farmakokinetičnih podatkov iz 3 zgoraj omenjenih študij in iz študije faze I pri bolnikih z mielodisplastičnim sindromom (N = 14; 15 mg/m2 v 3-urni infuziji vsakih 8 ur 3 dni).
English: For a typical patient (weight 70 kg/body surface area 1.73 m2) the decitabine pharmacokinetic parameters are listed in the Table 3 below.
Slovenian: Farmakokinetične lastnosti decitabina pri tipičnem bolniku (s telesno maso 70 kg/telesno površino 1,73 m2) so navedene v preglednici 3 spodaj.
English: Population PK analysis of decitabine showed that after accounting for body size, there is no difference between decitabine PK parameters in paediatric AML patients versus adults with AML or MDS.
Slovenian: Rezultati analize populacijske farmakokinetike decitabina so pokazali, da se ob upoštevanju telesne velikosti, farmakokinetični parametri decitabina pri pediatričnih bolnikih z AML ne razlikujejo od tovrstnih parametrov pri odraslih bolnikih z AML ali mielodisplastičnim sindromom.
English: Decitabine exhibits linear PK and following the intravenous infusion, steady-state concentrations are reached within 0.5 hour.
Slovenian: Decitabin ima linearno farmakokinetiko in po intravenski infuziji doseže stanje dinamičnega ravnovesja v 0,5 ure.
English: The use of Dacogen as initial therapy was also evaluated in an open-label, single-arm, Phase II study (DACO-017) in 55 subjects > 60 years with AML according to the WHO classification.
Slovenian: Uporabo zdravila Dacogen kot prvega zdravila so ocenjevali tudi v odprti študiji faze 2 z eno samo skupino (DACO-017) pri 55 bolnikih, ki so bili stari > 60 let in so imeli AML po klasifikaciji SZO.
English: It is unknown when it is safe for women to become pregnant after treatment has stopped.
Slovenian: Ni znano, kako dolgo po zaključku zdravljenja lahko ženska varno zanosi.
English: After reconstitution and dilution of the solution for intravenous infusion, this medicine contains less than 1 mmol (39 mg) of potassium per dose, i.e. essentially ‘potassium- free'.
Slovenian: Po rekonstituciji in razredčitvi raztopine za intravensko infundiranje to zdravilo vsebuje manj kot 1 mmol (39 mg) kalija na odmerek, kar v bistvu pomeni ‘brez kalija'.
English: 20 ml clear colourless Type I glass vial sealed with a butyl rubber stopper and an aluminium seal with plastic flip-off cap containing 50 mg decitabine.
Slovenian: 20-mililitrska viala iz prozornega brezbarvnega stekla tipa I, z butilnim gumijastim zamaškom in aluminijastim pokrovčkom s plastično dvižno zaporko; viala vsebuje 50 mg decitabina.
English: Decitabine Vdss in cancer patients is large indicating distribution into peripheral tissues.
Slovenian: Volumen porazdelitve decitabina v stanju dinamičnega ravnovesja (Vdss) je pri bolnikih z rakom velik, kar pomeni, da se porazdeli po perifernih tkivih.
English: Excretion of unchanged drug appears to play only a minor role in the elimination of decitabine.
Slovenian: Pri izločanju decitabina ima izločanje nespremenjene učinkovine le majhno vlogo.
English: Men should use effective contraceptive measures and be advised to not father a child while receiving Dacogen, and for 3 months following completion of treatment (see section 5.3).
Slovenian: Moške je treba opozoriti, naj v času zdravljenja z zdravilom Dacogen in še 3 mesece po njegovem zaključku uporabljajo učinkovito kontracepcijo, da ne bi spočeli otroka (glejte poglavje 5.3).
English: Liver function tests should be performed prior to initiation of therapy and prior to each treatment cycle, and as clinically indicated (see sections 4.2 and 5.2).
Slovenian: Delovanje jeter je treba preverjati pred uvedbo zdravljenja in pred vsakim krogom zdravljenja, v skladu s kliničnimi indikacijami (glejte poglavji 4.2 in 5.2).
English: Posology In a treatment cycle, Dacogen is administered at a dose of 20 mg/m body surface area by intravenous infusion over 1 hour repeated daily for 5 consecutive days (i.e., a total of 5 doses per treatment cycle).
Slovenian: Odmerjanje V enem krogu zdravljenja se zdravilo Dacogen aplicira v odmerku 20 mg/m2 telesne površine z intravensko infuzijo, ki traja najmanj 1 uro, in sicer 5 zaporednih dni (torej skupno 5 odmerkov v enem krogu zdravljenja).
English: The primary route of metabolism is likely through deamination by cytidine deaminase in the liver, kidney, intestinal epithelium and blood.
Slovenian: Presnova verjetno poteka predvsem z deaminacijo s citidin deaminazo, in sicer v jetrih, ledvicah, črevesnem epiteliju in krvi.
English: In clinical studies, 30% of patients treated with Dacogen and 25% of patients treated in the comparator arm had adverse events with an outcome of death during treatment or within 30 days after the last dose of study drug.
Slovenian: V kliničnih študijah so se pojavili neželeni učinki s smrtnim izidom med zdravljenjem ali v 30 dneh po zadnjem odmerku študijskega zdravila pri 30% bolnikov, ki so prejemali zdravilo Dacogen in pri 25% bolnikov v primerjalni skupini.
English: In the unlikely event that you are given too much (an overdose) your doctor will check you for side effects and manage them accordingly.
Slovenian: Če bi se zgodilo, da bi prejeli preveč zdravila (da bi prišlo do prevelikega odmerjanja), kar je sicer malo verjetno, vas bo zdravnik pregledal glede pojava neželenih učinkov.
English: The primary endpoint was complete remission (CR) rate that was assessed by independent expert review.
Slovenian: Primarni cilj opazovanja je bil delež bolnikov s popolno remisijo, ki je bila ocenjena s strani neodvisnega strokovnjaka.
English: Adverse drug reactions reported in 293 AML patients treated with Dacogen are summarised in Table 1.
Slovenian: V preglednici 1 so navedeni neželeni učinki, o katerih so poročali pri 293 bolnikih z AML, ki so prejemali zdravilo Dacogen.
English: Uncommon acute febrile neutrophilic dermatosis (Sweet's syndrome)
Slovenian: Bolezni kože in podkožja občasni akutna febrilna nevtrofilna dermatoza (Sweetov sindrom)
English: The need for dose adjustment in patients with hepatic impairment has not been evaluated.
Slovenian: Potrebe po prilagajanju odmerka pri bolnikih z okvaro jeter niso ocenili.
English: Table 3: Summary of population PK analysis for a typical patient receiving daily 1-hour infusions of Dacogen 20 mg/m2 over 5 days every 4 weeks
Slovenian: Preglednica 3: Povzetek rezultatov analize parametrov populacijske farmakokinetike pri tipičnem bolniku, ki je prejemal enourno intravensko infuzijo zdravila DACOGEN v odmerku 20 mg/m2 enkrat na dan 5 zaporednih dni vsake
English: In vitro metabolism data and the human mass balance study results indicated that the cytochrome P450 system is not involved in the metabolism of decitabine.
Slovenian: In vitro podatki o presnovi in rezultati študije masnega ravnovesja pri ljudeh kažejo, da encimski sistem s citokromom P450 ni vključen v presnovo decitabina.
English: Intracellularly, decitabine is activated through sequential phosphorylation via phosphokinase activities to the corresponding triphosphate, which is then incorporated by the DNA polymerase.
Slovenian: V celici fosfokinaze s sekvenčno fosforilacijo aktivirajo decitabin v ustrezen trifosfat, tega pa nato DNA polimeraze vgradijo v DNA.
English: The secondary endpoint was complete remission rate that was assessed by independent expert review.
Slovenian: Sekundarni cilj opazovanja je bil delež bolnikov, pri katerih pride do popolne remisije po oceni neodvisnega strokovnjaka.
English: Patients with favourable cytogenetics were not included in the study.
Slovenian: Bolnikov z ugodno citogenetiko niso vključili v študijo.
English: • Fever: this may be a sign of an infection caused by low levels of white blood cells (very common).
Slovenian: • Zvišana telesna temperatura: lahko je znak okužbe, do katere lahko pride zaradi zmanjšanega števila belih krvnih celic (zelo pogosto).
English: The most common Grade 3/4 adverse drug reactions (≥ 20%) included pneumonia, thrombocytopaenia, neutropaenia, febrile neutropaenia and anaemia.
Slovenian: Med najbolj pogostimi neželenimi učinki stopnje 3/4 (≥ 20%) so bili pljučnica, trombocitopenija, nevtropenija, febrilna nevtropenija in anemija.
English: How to use Dacogen
Slovenian: Kako uporabljati zdravilo Dacogen
English: Subjects who were considered candidates for standard induction chemotherapy were not included in the study as shown by the following baseline characteristics.
Slovenian: V študijo niso vključili bolnikov, ki so bili primerni za standardno indukcijsko kemoterapijo, kar je razvidno iz naslednjih izhodiščnih karakteristik.
English: A Phase I/II open-label, multicentre study evaluated the safety and efficacy of Dacogen in sequential administration with cytarabine in children aged 1 month to < 18 years with relapsed or refractory AML.
Slovenian: V odprti multicentrični študiji faze I/II so ocenjevali varnost in učinkovitost zdravila Dacogen z zaporednim odmerjanjem s citarabinom pri otrocih, ki so bili stari od 1 meseca do manj kot 18 let in so imeli recidivno ali neodzivno AML.
English: How Dacogen is given The solution is given into a vein (as an infusion).
Slovenian: Kako se daje zdravilo Dacogen Raztopino boste prejemali v veno (v obliki infuzije), kar bo trajalo eno uro.
English: If you forget your appointment to have Dacogen If you miss an appointment, make another one as soon as possible.
Slovenian: Če pozabite ali ne morete priti na infuzijo zdravila, se čimprej dogovorite za drug termin.
English: Dacogen contains potassium and sodium
Slovenian: Zdravilo Dacogen vsebuje kalij in natrij
English: When censored for potentially disease modifying subsequent therapy (i.e., induction chemotherapy or hypomethylating agent) the analysis for overall survival showed a 20% reduction in the risk of death for subjects in the Dacogen arm [HR = 0.80, (95% CI: 0.64, 0.99), p-value = 0.0437)].
Slovenian: Po cenzuriranju podatkov zaradi nadaljnje uporabe zdravil, ki potencialno lahko spreminjajo potek bolezni (torej indukcijske kemoterapije ali hipometilirajočih sredstev), kažejo rezultati analize celotnega preživetja 20-odstotno zmanjšano tveganje za smrt v skupini bolnikov, ki so prejemali zdravilo Dacogen [razmerje tveganja = 0,80, (95-odstotni IZ: 0,64; 0,99), vrednost p = 0,0437)].
English: • sore or runny nose, sore sinuses
Slovenian: • vnetje nosne sluznice ali izcedek iz nosu, vnetje sinusov
English: Renal function tests should be performed prior to initiation of therapy and prior to each treatment cycle, and as clinically indicated (see section 4.2).
Slovenian: Delovanje ledvic je treba preverjati pred uvedbo zdravljenja in pred vsakim krogom zdravljenja, v skladu s kliničnimi indikacijami (glejte poglavje 4.2).
English: In vitro studies show that decitabine does not inhibit nor induce CYP 450 enzymes up to more than 20-fold of the therapeutic maximum observed plasma concentration (Cmax).
Slovenian: Rezultati študij in vitro kažejo, da decitabin v koncentracijah, ki lahko presegajo 20-kratno najvišjo izmerjeno terapevtsko koncentracijo v plazmi (Cmax), niti ne zavira niti ne inducira encimov CYP 450.
English: Powder for concentrate for solution for infusion (powder for infusion).
Slovenian: prašek za koncentrat za raztopino za infundiranje (prašek za infuzijo)
English: Patients should be advised that they may experience undesirable effects such as anaemia during treatment.
Slovenian: Bolnike je treba opozoriti, da v času zdravljenja lahko pride do neželenih učinkov, kot je anemija, zato jim je treba priporočiti previdnost pri vožnji avtomobila ali upravljanju strojev.
English: • This medicine contains 0.5 mmol potassium in each vial.
Slovenian: • To zdravilo vsebuje 0,5 mmol kalija v eni viali.
English: It is recommended that patients be treated for a minimum of 4 cycles; however, a complete or partial remission may take longer than 4 cycles to be obtained.
Slovenian: Za popolno ali delno remisijo so lahko potrebni več kot 4 krogi zdravljenja.
English: This medicine contains 0.5 mmol potassium per vial.
Slovenian: To zdravilo vsebuje 0,5 mmol kalija na vialo.
English: Unopened vial: Do not store above 25C.
Slovenian: Zaprta viala : shranjujte pri temperaturi do 25 °C.
English: The major circulating metabolites are not believed to be pharmacologically active.
Slovenian: Domnevajo, da glavni presnovki v krvnem obtoku niso farmakološko aktivni.
English: Cardiac disease
Slovenian: Bolezni srca
English: Overall survival and complete remission rates in pre-specified disease-related sub-groups (i.e., cytogenetic risk, Eastern Cooperative Oncology Group [ECOG] score, age, type of AML, and baseline bone marrow blast count) were consistent with results for the overall study population.
Slovenian: V vnaprej določenih podskupinah glede na posamezne parametre bolezni (in sicer glede na citogenetsko stopnjo tveganja, oceno na lestvici ECOG [skupine Eastern Cooperative Oncology Group], starost, vrsto AML in izhodiščno število blastnih celic v kostnem mozgu) so bili celokupno preživetje in deleži bolnikov s popolno remisijo podobni kot v celotni študijski populaciji.
English: Dacogen was administered as a 1-hour intravenous infusion of 20 mg/m2 once daily for 5 consecutive days repeated every 4 weeks.
Slovenian: Zdravilo Dacogen so bolnikom aplicirali z enourno intravensko infuzijo v odmerku 20 mg/m2 enkrat na dan 5 zaporednih dni vsake 4 tedne.
English: Pack size: 1 vial.
Slovenian: Velikost pakiranja: 1 viala
English: Very common (may affect more than 1 in 10 people)
Slovenian: Pogosti (lahko se pojavijo pri največ 1 od 10 bolnikov)
English: Common septic shock* sepsis* sinusitis
Slovenian: b, c, d pogosti septični šok sepsa sinusitis
English: How Dacogen works Dacogen works by stopping cancer cells from growing.
Slovenian: Kako deluje zdravilo Dacogen Zdravilo Dacogen deluje tako, da zavira rast rakastih celic in jih tudi ubija.
English: The population PK analysis on the limited decitabine data indicated no significant PK parameter dependencies on normalized creatinine clearance, an indicator of renal function.
Slovenian: Rezultati analize populacijske farmakokinetike na podlagi omejenega obsega podatkov o decitabinu kažejo, da farmakokinetični parametri niso v večji meri odvisni od normaliziranega očistka kreatinina kot kazalca ledvične funkcije.
English: Cases of cardiomyopathy with cardiac decompensation, in some cases reversible after treatment discontinuation, dose reduction or corrective treatment, have been reported in the postmarketing setting.
Slovenian: Po prihodu zdravila na trg so poročali o primerih kardiomiopatije z dekompenzacijo srca, ki je v nekaterih primerih izzvenela po prekinitvi zdravljenja, zmanjšanju odmerka ali po prilagoditvi zdravljenja.
English: • Do not store above 25C.
Slovenian: • Shranjujte pri temperaturi do 25 °C.
English: Within 15 minutes of reconstitution, the solution must be further diluted with cold infusion fluids (sodium chloride 9 mg/ml [0.9%] solution for injection or 5% glucose solution for injection) to a final concentration of 0.15 to 1.0 mg/ml.
Slovenian: Raztopino je treba v 15 minutah po rekonstituciji dodatno razredčiti s hladnimi infuzijskimi tekočinami (9 mg/ml ([0,9%] raztopino natrijevega klorida za injiciranje ali 5-odstotno raztopino glukoze za injiciranje] do končne koncentracije od 0,15 do 1,0 mg/ml.
English: This prepared diluted solution for intravenous infusion can be stored at 2°C - 8°C for up to a maximum of 3 hours, followed by up to 1 hour at room temperature (20°C - 25°C) before administration.
Slovenian: Tako pripravljeno razredčeno raztopino za intravensko infundiranje je treba hraniti pri 2 °C - 8 °C, in sicer največ 3 ure, nato pa jo je pred uporabo mogoče največ 1 uro hraniti pri sobni temperaturi (20 °C - 25 °C).
English: Serious infection-related adverse drug reactions, with potentially fatal outcome, such as septic shock, sepsis, pneumonia, and other infections (viral, bacterial and fungal) were reported in patients receiving decitabine.
Slovenian: Pri bolnikih, ki so prejemali decitabin, so v povezavi z okužbami poročali o resnih neželenih učinkih z možnim smrtnim izidom, kot so septični šok, sepsa, pljučnica in druge okužbe (virusne, bakterijske in glivične).
English: Impact of decitabine on co-administered medicinal products Given its low in vitro plasma protein binding ( 1%), decitabine is unlikely to displace co-administered medicinal products from their plasma protein binding.
Slovenian: Glede na to, da se decitabin in vitro le v majhni meri veže na proteine v plazmi (< 1%), ni zelo verjetno, da bi izpodrival sočasno uporabljene učinkovine pri njihovi vezavi na proteine v plazmi.